RIG
ALXN

Roosevelt Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Roosevelt Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,925
Closed -$964K – 207
2016
Q1 		$964K Sell
6,925
-699
-9% -$103K 0.09% 102
2015
Q4 		$1.45M Sell
7,624
-250
-3% -$43.7K 0.1% 111
2015
Q3 		$1.23M Hold
7,874
– – 0.08% 121
2015
Q2 		$1.42M Sell
7,874
-100
-1% -$17.3K 0.08% 123
2015
Q1 		$1.38M Buy
7,974
+100
+1% +$18.1K 0.08% 118
2014
Q4 		$1.46M Sell
7,874
-358
-4% -$66.3K 0.08% 121
2014
Q3 		$1.36M Sell
8,232
-51
-0.6% -$8.38K 0.07% 121
2014
Q2 		$1.29M Sell
8,283
-2,889
-26% -$456K 0.06% 122
2014
Q1 		$1.7M Sell
11,172
-391
-3% -$62.2K 0.08% 103
2013
Q4 		$1.54M Buy
11,563
+267
+2% +$32K 0.07% 120
2013
Q3 		$1.31M Sell
11,296
-2,063
-15% -$226K 0.06% 125
2013
Q2 		$1.23M Buy
+13,359
New +$1.29M 0.06% 128

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Roosevelt Investment Group's ALXN Position: Q2 2016 in Review

Roosevelt Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 6,925 shares — an estimated $964K sold.

Roosevelt Investment Group first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $1.7M in Q1 2014. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Roosevelt Investment Group reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Roosevelt Investment Group sold 6,925 Alexion Pharmaceuticals shares in Q2 2016, an estimated $964K.
  • Roosevelt Investment Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Roosevelt Investment Group's Alexion Pharmaceuticals position peaked at $1.7M in Q1 2014.
  • 534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Roosevelt Investment Group's 13F filing for Q2 2016, filed 16 Aug 2016.